US FDA approves Zevra's treatment for rare genetic disease
Tweet
Share
E-mail
FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo
By Sriparna Roy
(Reuters) -The U.S. Food and Drug Administration has approved Zevra Therapeutics' drug for a rare and fatal genetic disorder, making it the first treatment to get a nod for the condition, the health regulator said on Friday.
The company has been trying for years to bring the drug to market after the FDA previously declined to approve it and extended a review of the treatment.
The oral drug, branded as Miplyffa, has now been approved for the treatment of Neimann-Pick disease type C - a rare genetic condition that affects the nervous system and other organs.
On average, people affected by this disease only live for about 13 years.
"The first-ever approval of a safe and effective drug option for NPC will undoubtedly support the essential medical needs of those suffering," said Janet Maynard, a director at the FDA's Center for Drug Evaluation and Research.
Miplyffa, in combination with miglustat, which is branded as Zavesca, has been cleared to treat neurological symptoms associated with NPC in adults and children 2 years of age and older.
The drug is expected to be available in the U.S. in eight to 12 weeks, Zevra said.
The company did not immediately respond to a Reuters request for comment on pricing.
H.C. Wainwright analyst Oren Livnat expects the average net price of the drug to between $500,000 and $600,000 per year.
Livnat estimates peak sales of about $250 million in the U.S.
Miplyffa comes with a warning for hypersensitivity reactions including hives and angioedema, a condition that causes swelling under the skin.
Zevra gained access to the drug through its acquisition of Orphazyme, the original developer, in 2022.
Shares of the company rose more than 5% to $8.43 in afternoon trading.
(Reporting by Sriparna Roy and Kashish Tandon in Bengaluru; Editing by Devika Syamnath and Alan Barona)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Reiterates Buy Rating on Zevra Therapeutics, Inc. (ZVRA)
- Gossamer Bio raises up to $250M in private placement for PAH drug
- FDA grants Nuvation Bio fast track status for brain cancer drug
Create E-mail Alert Related Categories
FDA, Hot FDA News, ReutersRelated Entities
Oren Livnat, Definitive Agreement, H.C. Wainwright, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
